09:01 , Jun 19, 2019 |  BC Extra  |  Financial News

Coenzyme A company Comet debuts with $28.5M series A

Led by former Syntimmune CEO David de Graaf, Comet launched Wednesday with $28.5 million in series A funding to develop precursors of coenzyme A to treat metabolic, immune and neurological disorders that involve dysregulated coenzyme...
20:58 , Jun 13, 2019 |  BC Innovations  |  Finance

Sitting it out: Why some investors are staying out of mega-series A rounds

As series A rounds continue to balloon, some VCs are opting to stay away from super-sized rounds, arguing the large boluses of cash up front can erode financial discipline and constrain exit options, hurting returns....
20:45 , Jun 13, 2019 |  BC Extra  |  Financial News

June 13 Financial Quick Takes: Hansoh prices $1B HKEX IPO; plus Provention, Genome Medical, InGeneron and more

Hansoh gets $10B-plus valuation via Hong Kong IPO  Hansoh Pharmaceutical Group Co. Ltd. (HKSE:03692) priced its Hong Kong IPO Thursday, raising HK$7.9 billion ($1 billion) through the sale of 551.3 million shares at HK$14.26. The...
22:18 , May 20, 2019 |  BioCentury  |  Product Development

Making Orphan drug prices work for society

The Orphan Drug Act worked too well. It didn’t just stimulate development of therapies for rare diseases, it reoriented huge swaths of the industry to the pursuit, all attracted by the high prices and product...
21:23 , May 3, 2019 |  BioCentury  |  Emerging Company Profile

Vineti: Keeping cell therapies on track

Drawing on its experience with CAR T cell therapies, Vineti has developed a cloud-based software platform that standardizes processes and drives down costs in the supply chain for personalized medicines. According to Vineti Inc. CEO...
21:25 , May 1, 2019 |  BC Extra  |  Company News

Management tracks: Gilead, bluebird, Apollomics

Gilead Sciences Inc. (NASDAQ:GILD) said Robin Washington will retire as EVP and CFO, effective March 1, 2020. Washington, who joined Gilead in 2008, will continue in her role while the company identifies a successor. Gene...
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
23:01 , Apr 19, 2019 |  BC Extra  |  Company News

Emerging company roundup: Kintai, Nocion, Arrakis and more

In a busy week for Boston-area biotechs, at least two companies debuted -- microbiome-mimicking small molecule company Kintai and pain play Nocion -- while a third, Arrakis, raised a $75 million series B round. Kintai...
21:28 , Apr 18, 2019 |  BC Extra  |  Financial News

RNA-targeting small molecule company Arrakis raises $75M series B

Arrakis raised $75 million in a series B round led by venBio and Nextech Invest. Also participating were new investors Omega Funds, HBM Healthcare Investments, GV, WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) and Alexandria Venture...
11:00 , Apr 18, 2019 |  BioCentury  |  Finance

Arranging Arrakis' syndicate

As it raised a $75 million series B round that will help its early research coalesce into a preclinical pipeline, Arrakis sought an investor syndicate that would build its expertise as it seeks to become...